the drug candidate was formerly known as ebola snalp tkm ebola is a combination of small interfering rnas targeting three of the seven proteins in ebola virus zaire ebola l polymerase zaire ebola membrane associated protein vp24 and zaire ebola polymerase complex protein vp35 by down regulating these three proteins tkm ebola inhibits virus replication and eliminates the infection the drug was effective in rhesus monkeys infected with ebola after the ebola outbreak in west africa in 2014 the new variant responsible for it was isolated from several ebola virus families and the specific genomic sequence was determined the company re designed tkm ebola and renamed it as tkm ebola guinea in january 2014 tekmira started a phase i clinical trial of tkm ebola to assess its safety in healthy people with a dose of 0 24 mg kg day for seven day treatments the fda placed the trial on clinical hold in july 2014 to assess results after some subjects had flu like responses in august the fda changed the status to partial hold allowing the drug to be used under expanded access in people infected with ebola but with the phase i trial still suspended in april 2015